United States· US:0069-0298_e850e390-b32e-4382-a2c7-d480c41bd3a6
Daurismo
A glasdegib product containing glasdegib, registered in United States by Pfizer Laboratories Div Pfizer Inc. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Glasdegib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XJ03 (glasdegib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 6 of them publish a price we can compare per daily dose
Glasdegib · ATC L01XJ03
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- GLASDEGIB
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- L01XJ03
- ATC class
- Glasdegib
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11006902986060 TABLET, FILM COATED in 1 BOTTLE (0069-0298-60)
- ndc110069-0298-60
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
478 interactions on record for glasdegib.
Graded by severity as the source publishes them — 125 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glasdegib · interactions on record
478 records
- 125 severe
- 345 moderate
- 8 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glasdegib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAURISMOPfizer Europe MA EEIG, Bruxelles
- SpainDAURISMO 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- FinlandDaurismoPfizer Europe MA EEIG
- IrelandDaurismo 25 mg film-coated tabletsPfizer Europe MA EEIG
- IcelandDaurismoPfizer Europe MA EEIG*
- NetherlandsDaurismo 25 mg, filmomhulde tablettenPfizer Europe MA EEIG
- PolandDaurismoPfizer Europe MA EEIG
- BelgiumDaurismo 25 mgPfizer Europe MA
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Daurismo
- Liechtenstein · Daurismo
- Norway · Daurismo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0f17801-ba74-4ac2-b1a5-ab13dbc5efab GET /v1/drugs/d0f17801-ba74-4ac2-b1a5-ab13dbc5efab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "25",
"substance": "GLASDEGIB",
"productndc": "0069-0298",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA210656",
"marketing_category": "NDA"
}See everything about glasdegib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.